Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
206.97
+1.82 (0.89%)
At close: Aug 10, 2026, 4:00 PM EDT
208.80
+1.83 (0.88%)
Pre-market: Aug 11, 2026, 7:43 AM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
44.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
RVMD News
- 1 day ago - BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration - Business Wire
- 5 days ago - Revolution Medicines Earnings Call Transcript: Q2 2026 - Transcripts
- 5 days ago - Revolution Medicines Earnings release: Q2 2026 - Filings
- 5 days ago - Revolution Medicines Quarterly report: Q2 2026 - Filings
- 5 days ago - Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 9 days ago - Revolution Medicines Slides: Corporate presentation - Filings
- 12 days ago - Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 - GlobeNewsWire
- 19 days ago - Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer - GlobeNewsWire